The Effects of Contact Lenses With UV/HEV-Filter on Visual Function

NCT ID: NCT05601544

Last Updated: 2025-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 145 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-09
• Study Completion Date: 2023-11-17

Brief Summary

This is a 2-phase, single-site, non-dispensing, randomized, controlled, double-masked, 2x2 crossover study to objectively measure potential benefits of a new UV/HEV filter using psychophysical testing techniques.

Conditions

Visual Acuity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Sphere TEST/CONTROL

Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.

Group Type: EXPERIMENTAL

ACUVUE OASYS 1-Day

Intervention Type: DEVICE

Sphere CONTROL

ACUVUE OASYS MAX 1-Day

Intervention Type: DEVICE

Sphere TEST

Sphere CONTROL/TEST

Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.

Group Type: EXPERIMENTAL

ACUVUE OASYS 1-Day

Intervention Type: DEVICE

Sphere CONTROL

ACUVUE OASYS MAX 1-Day

Intervention Type: DEVICE

Sphere TEST

Multifocal TEST/CONTROL

Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.

Group Type: EXPERIMENTAL

ACUVUE OASYS Multifocal

Intervention Type: DEVICE

Multifocal CONTROL

ACUVUE OASYS MAX 1-Day Multifocal

Intervention Type: DEVICE

Multifocal TEST

Multifocal CONTROL/TEST

Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.

Group Type: EXPERIMENTAL

ACUVUE OASYS Multifocal

Intervention Type: DEVICE

Multifocal CONTROL

ACUVUE OASYS MAX 1-Day Multifocal

Intervention Type: DEVICE

Multifocal TEST

Toric TEST/CONTROL

Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.

Group Type: EXPERIMENTAL

ACUVUE OASYS 1-Day for Astigmatism

Intervention Type: DEVICE

Toric CONTROL

senofilcon A based contact lens (toric) with new UV/HEV filter

Intervention Type: DEVICE

Toric TEST

Toric CONTROL/TEST

Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.

Group Type: EXPERIMENTAL

ACUVUE OASYS 1-Day for Astigmatism

Intervention Type: DEVICE

Toric CONTROL

senofilcon A based contact lens (toric) with new UV/HEV filter

Intervention Type: DEVICE

Toric TEST

Interventions

ACUVUE OASYS 1-Day

Sphere CONTROL

Intervention Type: DEVICE

ACUVUE OASYS MAX 1-Day

Sphere TEST

Intervention Type: DEVICE

ACUVUE OASYS Multifocal

Multifocal CONTROL

Intervention Type: DEVICE

ACUVUE OASYS MAX 1-Day Multifocal

Multifocal TEST

Intervention Type: DEVICE

ACUVUE OASYS 1-Day for Astigmatism

Toric CONTROL

Intervention Type: DEVICE

senofilcon A based contact lens (toric) with new UV/HEV filter

Toric TEST

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

The subject must:

1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.

3. Be between 18 and 70 (inclusive) years of age at the time of screening.

4. By self-report, habitually wear soft contact lenses (sphere, multifocal, toric) in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.

5. If applicable, those subjects receiving the spherical lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS

6. If applicable, those subjects receiving the multifocal lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS

7. If applicable, those subjects receiving the toric lenses will need a vertex-corrected distance refraction within the range of -1.50 through -4.00 DS, -0.625 through -1.625 DC, and cylinder axes: 80/90/100, 170/180/10

8. The best corrected, monocular, distance visual acuity must be 20/25 or better in each eye

Exclusion Criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

The subject must not:

1. Be currently pregnant or lactating.

2. Be currently using any ocular medications or have any ocular infection of any type.

3. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that the investigator believes might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.

4. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.

5. Be currently wearing lenses in an extended wear modality.

6. Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment.

7. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.

8. (Phase 2 only): Have participated in Phase 1 of the study.

9. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that the investigator believes might contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).

10. Have a history of strabismus or amblyopia.

11. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.

12. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Johnson & Johnson Vision Care, Inc. Clinical Trial

Role: STUDY_DIRECTOR

Johnson & Johnson Vision Care, Inc.

Locations

The University of Georgia

Athens, Georgia, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CR-6480

Identifier Type: -

Identifier Source: org_study_id